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Abstract: Measles virus is a highly contagious negative strand RNA virus that is transmitted via the
respiratory route and causes systemic disease in previously unexposed humans and non-human
primates. Measles is characterised by fever and skin rash and usually associated with cough, coryza
and conjunctivitis. A hallmark of measles is the transient immune suppression, leading to increased
susceptibility to opportunistic infections. At the same time, the disease is paradoxically associated
with induction of a robust virus-specific immune response, resulting in lifelong immunity to measles.
Identification of CD150 and nectin-4 as cellular receptors for measles virus has led to new perspectives
on tropism and pathogenesis. In vivo studies in non-human primates have shown that the virus
initially infects CD150+ lymphocytes and dendritic cells, both in circulation and in lymphoid tissues,
followed by virus transmission to nectin-4 expressing epithelial cells. The abilities of the virus to cause
systemic infection, to transmit to numerous new hosts via droplets or aerosols and to suppress the
host immune response for several months or even years after infection make measles a remarkable
disease. This review briefly highlights current topics in studies of measles virus host invasion
and pathogenesis.
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1. Introduction
Measles virus (MV) is the prototype member of the genus Morbillivirus, the subfamily
Paramyxovirinae and the family Paramyxoviridae. MV is an enveloped virus with a single strand,
non-segmented negative sense RNA genome and exclusively causes disease in old- and new-world
non-human primates (NHPs) and humans. Like all morbilliviruses, MV is highly contagious and is
transmitted via the respiratory route [1]. Once the virus is inhaled and a primary target cell is infected,
systemic spread ensues and clinical signs appear after 9–19 days. The prodromal stage starts with fever
and malaise associated with cough, coryza and conjunctivitis, colloquially the three “C’s”. During this
stage Koplik’s spots can be observed on the buccal mucosa. On the subsequent days patients develop
a maculopapular skin rash that starts behind the ears and spreads to the face, trunk and extremities [2,3].
MV infection is usually self-limiting, due to the clearance of virus-infected cells by the immune system.
Recovery is followed by lifelong immunity to measles. In rare cases, severe measles-associated
central nervous system (CNS) complications may develop: Acute disseminated encephalomyelitis
(ADEM), measles inclusion body encephalitis (MIBE) or subacute sclerosing panencephalitis (SSPE).
MV infection paradoxically also results in a transient immune suppression that may last over two years
after infection and leads to opportunistic infections and increased mortality risk [4]. The World Health
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Organisation (WHO) estimated that approximately 114,900 people, mostly children under five years of
age, died of measles and resulting sequelae in 2014 [5].
Signalling lymphocyte activation molecule family member 1 (SLAMF1, also known as CD150),
which is expressed by subsets of thymocytes, dendritic cells (DCs), haematopoietic stem cells (HSCs),
macrophages, T- and B-cells, has been identified as a cellular receptor for MV [2,6,7]. Infection of NHPs
with recombinant MV (rMV) derived from the wild-type Japanese IC323 strain and engineered to
express a fluorescent reporter protein identified CD150+ lymphocytes and DCs as predominant target
cells of MV infection in vivo [8]. Nectin cell adhesion molecule 4 (nectin-4, previously also known as
poliovirus receptor-related 4 or PVRL4) has been identified as another cellular receptor for MV that
is expressed by epithelial cells [9,10]. This protein is part of the adherens junction complex, which
is located at the basolateral side of the epithelium, underneath the tight junctions. Nectin-4 is also
expressed by keratinocytes [11,12] and endothelial cells [13], suggesting a potential role for these cell
types in the pathogenesis of the characteristic measles skin rash [13–15].
Both CD150 and nectin-4 play crucial roles in the pathogenesis of measles. Vaccine and
laboratory-adapted MV strains can utilise CD46 as an additional cellular receptor in vitro, but this
receptor does not seem to play a major role during infection with these viruses in vivo [16,17]. The C-type
lectins DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and Langerin,
expressed by DCs and Langerhans cells, respectively, have been identified as attachment receptors for
MV. However, these molecules do not mediate MV entry, but are thought to “capture” MV particles
and facilitate CD150-mediated virus-to-cell fusion of DCs or lymphocytes [18,19]. The following review
of MV entry, dissemination, transmission and immune suppression is largely based on observations
from experimental MV infections of NHPs.
2. Entry
Respiratory epithelial cells have classically been considered as the early target cells of MV infection
in the respiratory tract. However, the lack of CD150 or nectin-4 expression on their apical surface
renders this entry mechanism unlikely. NHPs infected with rMV that was unable to recognise nectin-4
(referred to as “nectin-4-blind” virus) still led to the establishment of systemic infection [20], whereas
animals infected with an rMV that was unable to recognise CD150 (“CD150-blind”) failed to develop
clinical signs or viremia [21]. These findings highlight the importance of CD150 during viral entry
and exclude respiratory epithelial cells as the primary target cells, although it cannot be excluded that
receptor-binding modifications have led to a generalized attenuation and loss of viral fitness.
In vivo studies with NHPs experimentally infected with rMV expressing enhanced green
fluorescent protein (EGFP) identified CD11c+ myeloid cells, most likely alveolar macrophages and
DCs, in the lungs and respiratory submucosa as potential early target cells [8,22,23]. Two mechanisms
of MV entry were proposed based on these findings: infection of CD150+ cells in the alveolar spaces or
binding to dendrites of DC-SIGN+ submucosal DCs in the lumen of the respiratory tract, followed
by migration to tertiary lymphoid tissues, such as the bronchus-associated lymphoid tissue [24], and
draining lymph nodes [8,25,26], where the infection is subsequently amplified by massive replication
in abundantly present CD150+ B- and T-cells [8,27]. These potential routes of entry are illustrated
in Figure 1.
Another possible, but probably less important, route of MV entry is through MV infection of
myeloid or lymphoid cells in the conjunctiva. The lamina propria of the conjunctiva is rich in DCs,
Langerhans cells, macrophages, CD4+ and CD8+ T-cells and B-cells, providing a suitable site of
replication for the virus [28]. This infection and the ensuing MV-specific immune response may
subsequently lead to prodromal conjunctivitis [29]. In addition to the conjunctiva, MV has been shown
to infect human corneal rim epithelial cells ex vivo [30]. It has been reported that eye protection during
contact with measles patients can reduce the risk of contracting infection by MV [31].
Viruses 2016, 8, 210 3 of 13
Viruses 2016, 8, x 3 of 13 
 
Invasion of the respiratory tract by bacteria or other pathogens causing damage to the epithelial 
layer could be advantageous for MV entry. MV inoculated onto the apical side of well-differentiated 
ciliated bronchial epithelial cell cultures did not result in infection. However, wounding of the 
human bronchial epithelial cell in vitro resulted in numerous foci of infection along the lines of the 
wound, possibly due to the disruption of the tight junctions at cell-to-cell contacts and the 
subsequent exposure of nectin-4 as a cellular receptor [30,32]. It is possible that MV can infect the 
respiratory tract through similar epithelial disruption in vivo, either as a result of infection or 
mechanical damage [30,33]. However, the highly efficient transmission of MV from infected to naive 
individuals and the susceptibility of every measles-naive human to MV infection suggests that 
infectious predisposition is not a requirement for efficient MV entry. 
 
Figure 1. The first stage of MV infection: entry of MV into a susceptible host. The virus enters the 
respiratory tract (green arrows in panels (C) and (E)), where it binds to DC-SIGN+ DCs or infects 
CD150+ myeloid or lymphoid cells in the mucocilliary epithelium or the alveolar spaces. Another 
potential site of entry is through the conjunctiva, which is rich in DCs and CD150+ lymphocytes (A). 
Panels on the right show an enlarged illustration of potential entry events. MV particles deposited on 
the conjunctiva will enter the space between cornea and eyelids ((A), green arrows), where they can 
infect myeloid or lymphoid cells (B). MV particles inhaled into the respiratory tract ((C) and (E), 
green arrows) can either infect DC-SIGN+ dendritic cells in the upper respiratory tract, with 
dendrites protruding into the respiratory mucosa (D), or dendritic cells or macrophages in the 
alveolar lumina of the lower respiratory tract (F). The infected immune cells subsequently migrate to 
nearby tertiary lymphoid tissues and draining lymph nodes (black). 
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are major sites of MV replication in vivo [8,25,27,34–37]. Analysis of lymphoid tissues of 
experimentally infected NHPs showed prominent MV replication in B-cell follicles [8,25]. 
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Invasion of the respiratory tract by bacteria or other pathogens causing damage to the epithelial
layer could be advant geous for MV entry. MV inoculated ont the apical side of well-differentiated
ciliated bronchi l epithelial cell c ltures did not result in infection. However, wounding of the
human bronchial epithelial cell in vitro resulted in numerous foci of infection along the lines of the
wound, possibly du to the disruption of the tight junctions at c ll-to-cell co tacts and the subsequent
exposure of nectin-4 as a cellular receptor [30,32]. It is possible that MV can infect the respiratory tract
through similar epithelial disruption in viv , either as a result of infection or mechanical damage [30,33].
However, the highly efficient transmission of MV from infected to naive individuals and the
susceptibility of every measles-naive human to MV infection suggests that infectious predisposition is
not a requirement for efficient MV entry.
3. Dissemination
Primary (bone marrow and thymus), secondary (spleen, tonsils, lymph nodes) and tertiary (e.g.,
bronchus-associated lymphoid tissue (BALT)) lymphoid tissues are rich in CD150+ lymphocytes and
are major sites of MV replication in vivo [8,25,27,34–37]. Analysis of lymphoid tissues of experimentally
infected NHPs showed prominent MV replication in B-cell follicles [8,25]. Multinucleated giant cells or
syncytia, known as Warthin-Finkeldey cells, were especially observed in lymphoid tissues in the upper
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respiratory tract [25,38–40] and consisted of fused B-cells [8,27]. In addition to B-cells, widespread MV
infection of both CD4+ and CD8+ CD150+ memory T-cells was observed in these tissues.
Viral dissemination is predominantly mediated by cell-to-cell transmission of virus [32,41,42].
In MV-infected NHPs, infected cells in peripheral tissues were mostly interconnected by dendrites.
Widespread infection of lymphoid tissues is followed by infection of lymphocytes and DCs in the skin
and the epithelial submucosa (Figure 2A). Here, infected lymphocytes or DCs transmit the virus to the
neighbouring nectin-4+ epithelial cells [30,43,44] or keratinocytes. Nectins can form both homodimers
and heterodimers at cell-to-cell junctions, but the heterodimer interactions have been shown to be more
stable. The disruption of nectin-4 and nectin-1 heterodimers by MV has been suggested to facilitate
viral spread [45].
MV spreads systemically to other organs and tissues, such as the gastrointestinal tract, kidney, liver
and skin through infected circulating CD150+ immune cells (Figure 2B), and, in some rare cases, infects
endothelial cells, neurons, astrocytes and oligodendrocytes in vivo [3,46]. MV infection stimulates the
expression and activation of the leukocyte integrins lymphocyte function associated antigen-1 and
very late activation antigen-4 [47]. These molecules allow adherence of infected migrating cells to
the endothelial cells and subsequent trans-migration into the tissues [46,47]. Infection of endothelial
cells with MV in vitro stimulates the production of colony-stimulating factor and thus increases the
adhesion of granulocytes to infected epithelial cells [48]. MV antigens were found in the capillary
endothelium of lymph nodes and thymus in patients who died from the infection [49].
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Figure 2. The second stage of MV infection: systemic dissemination. (A) The MV-infected myeloid cells
migrate to the draining lymph nodes (black), where they transmit the virus to CD150+ lymphocytes
(predominantly B-cells and memory CD4+ and CD8+ T-cells); (B) during viremia infected cells enter
the circulation and migrate systemically to various organs and tissues (green), where the infection is
further amplified. Infection of skin-resident immune cells results in virus transmission to nectin-4+
epithelial cells (green patches); (C) a few days later, depletion of immune cells in lymphoid organs and
tissues results in transient immune suppression (grey). MV-specific T-cells infiltrate the skin where
they clear the infected cells, which results in the typical measles skin rash (red patches). The green
bell-shaped curve in the background represents the viral load over time.
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MV can also infect permissive cells through receptor-independent mechanisms [50], although
these mechanisms are much less efficient than receptor-mediated entry. One of the possible mechanisms
is through an in-cell infection. This mechanism has been identified in allowing Epstein-Barr virus
(EBV) spread from infected B-cells to epithelial cells by internalisation of the EBV-infected B-cells
into carcinoma cells, resulting in activation and transfer of the virus to the carcinoma cells in vitro
and in vivo [51]. It is tempting to speculate that MV-infected lymphocytes can also be internalised by
receptor-negative cells, leading to infection.
Clinical measles starts with the emergence of Koplik’s spots on the buccal mucosa and
culminates a few days later in the appearance of the maculopapular skin rash (Figure 2C) [3].
Histological examinations showed that the characteristics of the Koplik’s spots were similar to those of
the skin rash and they may contain syncytia [52]. The rash can potentially be explained by infection of
the dermal endothelial cells and keratinocytes, which are subsequently cleared by the virus-specific
host cellular immune response [3]. Several studies reported that viral antigens were found in the
corneal layer, spongiotic epidermal keratinocytes and even more in the dermal papillary layer [15].
The skin lesions were characterised with spongiosis, cell necrosis and mononuclear cell infiltration of
the epidermal keratinocytes [14,15]. The crucial role of the host immune response in the pathogenesis
of the skin rash is illustrated by the fact that immunocompromised patients often do not develop skin
rash following MV infection, although the course of a MV infection in these patients is typically severe
and can be lethal [53].
Although most measles cases resolve without complications, the virus can remain persistent
and infect the CNS on rare occasions. One of the neurologic complications, known as the ADEM, is
immune-mediated and has a higher incidence and severity than the other complications (~1:1000).
Although the induction of this autoimmune response is poorly understood, “molecular mimicry”
based on structural similarities between MV proteins and myelin has been suggested as a pathogenic
mechanism [54,55]. The disease is hallmarked by demyelination, which results in ataxia, motor and
sensory loss and mental status changes [56] and can result in death.
A second neurologic complication stemming from systemic MV infection is MIBE. The risk of
developing MIBE increases when the MV infection occurs in young infants or immunocompromised
individuals, who are unable to clear the infection. The symptoms of MIBE often include mental
status changes, focal seizures and occasionally visual or hearing loss within one year of acute measles
infection or live-virus vaccination [57,58]. The disease progresses rapidly to coma and death in the
majority of patients [54].
A third and very rare neurological complication of measles is SSPE. Symptoms develop several
years after a normal episode of measles and usually start with a decline of school performance and
a slight change of behaviour, progressively followed by myoclonic seizures, ataxia and death within
one to three years [25,59]. SSPE is exclusively associated with infections with wild-type MV, and
has never been observed in association with genotype A vaccine viruses. Where the virus persists
and how it spreads in the CNS remains unknown. It has been suggested that the virus spreads
from one neuron to the other through interconnecting processes in vitro and in vivo, without the
release of infectious particles [60–62]. This infection may rely on membrane fusion between infected
and uninfected neurons, allowing trans-synaptic transmission of ribonucleoprotein (RNP) [25,63,64].
The RNP consists of genomic viral RNA encapsidated with the viral nucleoprotein and associated
with the viral polymerase, and is the minimal unit of infection [3]. MV-positive oligodendrocytes and
astrocytes were also found in the white matter of SSPE cases. The virus may spread from one glial cell
to another via interconnected processes [25].
It is still unclear how MV enters the CNS, however in recent years it has become apparent that
the blood-brain-barrier allows entry of lymphocytes into the brain [65,66]. Moreover, it has been
shown that the brain even contains lymphatic vessels [67]. Therefore, infected lymphocytes circulating
in peripheral blood during viremia could carry the virus into the CNS, where the virus could be
transmitted via a yet unknown cellular entry receptor or receptor-independent entry mechanisms.
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4. Transmission
The basic reproductive number (R0) reflects the average number of secondary cases that would
arise when an infectious agent is introduced into a completely susceptible population [68]. MV is
released into the air as cell-free or cell-associated virus particles, predominantly by coughing [9,10,69].
The virus is highly infectious: the estimated R0 is 12 to 18 [68]. In specific cases individual patients have
been reported to more than 200 new patients [70], often referred to as “superspreading” events [71].
The high infectivity of MV can be attributed to three crucial transmission properties. First,
measles patients must efficiently shed MV. Tracheo-bronchial epithelial cells have been reported to
be susceptible to MV infection [10,25,43,44], associated with epithelial damage in the bronchi and
bronchioles [27,43]. Whereas epithelial cells are infected from the basolateral side, budding occurs
exclusively at the apical cell surface due to sorting signals in the viral glycoproteins. Whilst MV
particles produced in the lymphoid tissues can rapidly bind to neighbouring CD150+ cells that are
highly abundant in the environment, MV particles produced by the respiratory epithelial cells will
be shed into the mucus lining the lumen of the respiratory tract where cells expressing MV receptors
are scarce. Hence, virions remain in the mucus as cell-free particles, and are moved to the upper
respiratory tract (URT) by the mucocilliary escalator [43] and discharged into the environment by
coughing. MV can be transmitted by large respiratory droplets (by direct contact) or in small aerosols
transported through the air over long distances [72]. The release of new MV particles from the host
into the air is illustrated in Figure 3.
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Second, the virus must remain infectious until it reaches a new host. Large droplets may increase
the stability of cell-bound MV particles or cell debris that are expelled from the body, allowing the
virus to survive long enough until it comes into contact with the eyes, nose or mouth of a susceptible
person. Alternatively, cell-free virions transmitted airborne as small aerosols through a turbulent
airflow may survive in air for at least one hour, as demonstrated during the outbreaks of measles in
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a paediatric practice in 1981 and at an International Special Olympics Games in 1995 [72,73]. One of
the factors that influence survival of MV in the air is relative humidity: in aerosols, the virus is most
stable below 40% or above 80% [74].
The last vital transmission property concerns the infectious dose of the virus. In NHPs, a single
50% tissue culture infectious dose was shown to be sufficient to establish a productive infection
associated with systemic dissemination [75]. However, measles patients shed large amounts of virus,
resulting in transmission of numerous infectious units. The combination of large inoculum and low
infectious dose may increase the chance of rapid deposition of virus particles in the respiratory tract of
the next host, especially in a crowded and poorly ventilated environment [73].
5. Immune Suppression
MV infection results in a transient and profound immune suppression, which leads to increased
susceptibility to opportunistic infections and increased childhood mortality [4]. The virus efficiently
replicates in lymphoid tissues. Tertiary lymphoid tissues, such as BALT and gut associated lymphoid
tissues (GALT), can be induced by bacterial or viral infection that leads to the accumulation and
proliferation of lymphocytes and the formation of germinal centres. CD11c+ DCs and follicular DCs
are present within to maintain the structure of these tissues [76,77]. The presence and interaction of
CD150+ lymphocytes and DC-SIGN+ DCs in these tissues consequently makes them the perfect site
for MV infection and amplification [8,27]. Since BALT and GALT are known to enhance protective
immunity against mucosal pathogens, obliteration of these lymphoid tissues that are present in major
entry portals for opportunistic infections (the airways and gut) can facilitate infiltration of the mucosa
by previously encountered viruses or bacteria.
MV infection leads to lymphopenia during its acute phase, in which the number of T- and
B-cells, both circulating and lymphoid tissue homing, decreases extensively (Figure 2C) [27,78].
Peak numbers of MV-infected cells in lymphoid tissues of experimentally infected NHPs coincide with
the peak of viremia, rapidly followed by B-cell exhaustion in the germinal centres [27], as previously
also reported in humans [38]. The infection induces an expansive effector phase, leading to the
clearance of MV-infected cells by cytotoxic T-cells [79] and subsequently a lifelong measles-specific
immune response [80]. Following viral clearance, the number of lymphocytes returns to normal
within approximately one week. However, while the lymphopenia lasts for a week, the immune
suppression may last variably from several weeks to up to more than two years [4]. This led
to the initial dismissal of the role of immune cell depletion in causing measles-induced immune
suppression [81]. Instead, functional impairment of the immune cells has often been proposed to
explain the mechanism of the immune suppression. However, there is limited evidence that this is
the case and it has proven difficult to identify a cell surface receptor that mediates suppression of
proliferation in immune cells. Reduced proliferative responsiveness of peripheral blood lymphocytes
to antigenic or mitogenic stimulation has also been suggested as a mechanism of measles immune
suppression. Although this impairment is indeed detected in vitro, measles is associated with dramatic
levels of lymphoproliferation in vivo [27]. Other mechanisms have been proposed to explain the
nature of the measles-induced immune suppression, such as altered cytokine profiles [82–85] or
inhibited haematopoiesis [86,87], but none of these fit with the measles paradox: Prolonged increased
susceptibility to infectious disease and coinciding induction of strong MV-specific immune responses.
Based on observations in experimentally infected NHPs we proposed an alternative model
explaining measles immune suppression, based on the preferential infection and subsequent
immune-mediated depletion of CD150+ memory T- and B-cells, resulting in “immune amnesia” [27,88].
The loss of memory lymphocytes is masked by a massive expansion of new MV-specific and bystander
lymphocytes, explaining the short duration of lymphopenia and yet the long duration of immune
suppression. This finding thus revives the importance of immune cell depletion as a key mechanism
for measles-associated immune suppression.
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Mechanisms underlying MV entry, dissemination, transmission and immune suppression as
discussed in this review are illustrated with images from experimentally infected NHPs in Figure 4.Viruses 2016, 8, x 8 of 13 
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6. Conclusions 
Measles has caused a high number of fatalities throughout history. Recombinant viruses 
expressing fluorescent reporter proteins have given us the means to study and understand the virus 
and its pathogenesis from a new perspective. However, these advances not only leave some old 
mysteries concerning measles pathogenesis unexplained, but also give birth to new questions. Since 
global eradication of measles is planned for the near future, studies on MV tropism and 
pathogenesis not only remain important, but also become urgent [89]. 
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